Given the subdivision of osteosarcoma into ALT+ and ALT− categories, where ALT+ exhibits a more open chromatin level in the telomere region compared to ALT−, we sought to determine if methotrexate exhibits differential sensitivity in these subtypes, aiming to offer improved guidance for clinical medication. This evidence concerns the gene GPT and osteosarcoma.